Neurology Unit, Neuromotor & Rehabilitation Department, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy.
Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41125 Modena, Italy.
Biomolecules. 2024 Aug 17;14(8):1022. doi: 10.3390/biom14081022.
Neurosteroids are pleiotropic molecules involved in various neurodegenerative diseases with neuroinflammation. We assessed neurosteroids' serum levels in a cohort of Parkinson's Disease (PD) patients with heterozygous glucocerebrosidase (GBA) mutations (GBA-PD) compared with matched cohorts of consecutive non-mutated PD (NM-PD) patients and healthy subjects with (GBA-HC) and without (NM-HC) GBA mutations. A consecutive cohort of GBA-PD was paired for age, sex, disease duration, Hoehn and Yahr stage, and comorbidities with a cohort of consecutive NM-PD. Two cohorts of GBA-HC and HC were also considered. Clinical assessment included the Movement Disorder Society revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and the Montreal Cognitive Assessment (MoCA). Serum samples were processed and analyzed by liquid chromatography coupled with the triple quadrupole mass spectrometry. Twenty-two GBA-PD (males: 11, age: 63.68), 22 NM-PD (males: 11, age: 63.05), 14 GBA-HC (males: 8; age: 49.36), and 15 HC (males: 4; age: 60.60) were studied. Compared to NM-PD, GBA-PD showed more hallucinations and psychosis ( < 0.05, Fisher's exact test) and higher MDS-UPDRS part-II ( < 0.05). Most of the serum neurosteroids were reduced in both GBA-PD and NM-PD compared to the respective control cohorts, except for 5α-dihydroprogesterone. Allopregnanolone was the only neurosteroid significantly lower ( < 0.01, Dunn's test) in NM-PD compared to GBA-PD patients. Only in GBA-PD, allopregnanolone, and pregnanolone levels correlated (Spearman) with a more severe MDS-UPDRS part-III. Allopregnanolone levels also negatively correlated with MoCA scores, and pregnanolone levels correlated with more pronounced bradykinesia. This pilot study provides the first observation of changes in neurosteroid peripheral levels in GBA-PD. The involvement of the observed changes in the development of neuropsychological and motor symptoms of GBA-PD deserves further attention.
神经甾体是涉及多种神经退行性疾病伴神经炎症的多效分子。我们评估了帕金森病(PD)患者杂合半乳糖脑苷脂酶(GBA)突变(GBA-PD)与连续未突变 PD(NM-PD)患者和具有(GBA-HC)和不具有(NM-HC)GBA 突变的健康对照者的血清神经甾体水平。连续的 GBA-PD 队列与年龄、性别、疾病持续时间、Hoehn 和 Yahr 分期以及与 NM-PD 队列相匹配的共病进行配对。还考虑了两个 GBA-HC 和 HC 队列。临床评估包括运动障碍协会修订的统一帕金森病评定量表(MDS-UPDRS)和蒙特利尔认知评估(MoCA)。通过液相色谱-串联三重四极杆质谱法处理和分析血清样本。研究了 22 名 GBA-PD(男性:11 名,年龄:63.68)、22 名 NM-PD(男性:11 名,年龄:63.05)、14 名 GBA-HC(男性:8 名,年龄:49.36)和 15 名 HC(男性:4 名,年龄:60.60)。与 NM-PD 相比,GBA-PD 表现出更多的幻觉和精神病(<0.05,Fisher 确切检验)和更高的 MDS-UPDRS 第二部分(<0.05)。与各自的对照队列相比,大多数血清神经甾体在 GBA-PD 和 NM-PD 中均降低,除了 5α-二氢孕酮。与 NM-PD 相比,GBA-PD 患者的所有孕烯醇酮明显降低(<0.01,Dunn 检验)。只有在 GBA-PD 中,所有孕烯醇酮和孕烷醇酮水平呈正相关(Spearman)与更严重的 MDS-UPDRS 第三部分。所有孕烯醇酮水平也与 MoCA 评分呈负相关,而孕烷醇酮水平与更明显的运动徐缓相关。这项初步研究提供了 GBA-PD 中外周神经甾体水平变化的首次观察。观察到的变化在 GBA-PD 神经心理和运动症状的发展中的参与值得进一步关注。